Guggenheim analyst Subbu Nambi lowered the firm’s price target on GeneDx (WGS) to $100 from $170 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for select companies in its diagnostics and life science tools coverage to reflect recent updates from the companies after meetings with management teams.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- Cathie Wood Invests Over $10M in CRISPR and PAYP Stocks, Trims Stakes in TER and IONS
- GeneDx data could support improved coverage, says Craig-Hallum
- Natera announces commercial launch of Zenith genomics
- GeneDx falls after Natera launches sequencing assay for rare diseases
- CRSP, SOLQ: Cathie Wood’s ARK ‘Buys the Dip’ in CRISPR and Solana Staking ETF